New Alzheimer’s Drugs 2026: Donanemab & Lecanemab Breakdown
Key Takeaways
- A Shift in Paradigm: A breakthrough in medical history, treatments like Lecanemab (Leqembi) and Donanemab (Kisunla) target the underlying biology of Alzheimer’s rather than just masking symptoms.
- Clinical Efficacy: Donanemab has shown a 35% slowing of clinical decline in early-stage patients, while Lecanemab demonstrated a 27% slowing in its primary global trial.
- Targeted Population: These drugs are strictly indicated for patients in the earliest stages: Mild Cognitive Impairment (MCI) or mild dementia due to Alzheimer’s.
- Safety Profile: The primary clinical concern is ARIA (Amyloid-Related Imaging Abnormalities), requiring rigorous MRI monitoring and, in many cases, genetic testing for the APOE4 variant.
- Availability: While Health Canada approved Lecanemab in late 2025 and Donanemab in May 2026, public funding and infrastructure hurdles mean a “ramp-up” period for patient access.
Introduction
For over two decades, the “standard of care” for Alzheimer’s disease was defined by a frustrating ceiling. Medications like Donepezil or Memantine offered a temporary chemical boost to aid memory, but they did nothing to stop the slow, structural dismantling of the brain.
That ceiling has finally been shattered. Between late 2025 and May 2026, Health Canada authorized a new class of monoclonal antibodies: Lecanemab and Donanemab, that represent the first “disease-modifying” therapies in the country. This isn’t just another pill for memory; it is a mechanical intervention in the brain’s chemical environment.
The “Amyloid Hypothesis” in Action: How These Antibodies Work
To understand how these drugs work, we must look at the “trash” that accumulates in an Alzheimer’s brain. A protein called amyloid-beta begins to clump together, forming sticky “plaques” that disrupt communication between neurons and eventually trigger their death.
Both Lecanemab and Donanemab are humanized IgG1 monoclonal antibodies, but they are engineered to seek out slightly different forms of this “trash”:
- Lecanemab (Leqembi): It focuses on protofibrils: intermediate, highly toxic strands of amyloid that are on their way to becoming plaques. By neutralizing these, it prevents the further seeding of the disease.
- Donanemab (Kisunla): This drug is more “surgical.” It targets a specific form of amyloid called N-terminal pyroglutamate, which is only found in established, insoluble brain plaques.
By binding to these targets, the drugs signal the brain’s own immune cells (microglia) to “eat” and remove the plaques. In clinical trials, many patients on Donanemab saw their plaque levels drop so low that they were effectively “amyloid-negative” after just a year of treatment.
Lecanemab (Leqembi): Breaking the 20-Year Drought
Approved by Health Canada on October 25, 2025, Lecanemab was the historic first. The Clarity AD trial, which formed the basis of its approval, followed nearly 1,800 patients over 18 months.
The results were statistically significant: a 27% reduction in clinical decline. For a patient, this might translate to several extra months or years of being able to live independently, manage finances, or recognize family members.
Dosing and Administration: Lecanemab is typically administered via intravenous (IV) infusion once every two weeks. However, as of May 2026, research into subcutaneous (under-the-skin) versions is accelerating, which could eventually allow for at-home administration, significantly reducing the burden on hospital infusion centers.
Donanemab (Kisunla): The Milestone of Plaque Clearance
The approval of Donanemab on May 1, 2026, added a powerful second tool to the Canadian clinical arsenal. The TRAILBLAZER-ALZ 2 trial showed that Donanemab slowed cognitive and functional decline by 35% in a group of patients with low-to-medium levels of another toxic protein called tau.
One of the most unique technical aspects of Donanemab is the “Limited-Duration” treatment model. Unlike most chronic medications that are taken for life, Donanemab treatment can be paused once PET scans show the brain has been cleared of plaques. This “treat-to-clear” approach is a potential game changer for both patient quality of life and healthcare system costs.
Clinical Vigilance: Understanding ARIA and the APOE4 Factor
The phrase “disease-modifying” comes with a significant caveat: these drugs are biologically “loud,” and they can cause side effects that require expert monitoring. The most common is ARIA (Amyloid-Related Imaging Abnormalities).
- ARIA-E (Edema): Temporary swelling in the brain.
- ARIA-H (Hemorrhage): Small microbleeds on the brain’s surface.
While most ARIA cases are asymptomatic and resolve on their own, they can occasionally be severe or even fatal. The risk is significantly higher in patients who carry two copies of the APOE4 gene variant, the strongest genetic risk factor for Alzheimer’s. Consequently, Health Canada and the Alzheimer Society emphasize that patients should undergo genetic testing and frequent MRI monitoring (often at weeks third, fifth, seventh, and fourteenth of treatment) to ensure safety.
What the Alzheimer Society of Canada Has to Say
The approval of Donanemab hasn’t just resonated in medical journals; it has sent a wave of cautious optimism through the Alzheimer Society of Canada (ASC). In their official national statement, the Society describes this moment as a “significant milestone” and the dawn of a new era for the over 650,000 Canadians living with dementia.
However, the ASC’s stance is one of balanced advocacy. They are clear that while the science has arrived, the healthcare system may not yet be ready to deliver it.
The ASC emphasizes that these drugs are not for everyone. They are designed specifically for people in the early stages of the disease. This makes early and accurate diagnosis more critical than ever before. If a patient is diagnosed too late, the “window of opportunity” for these disease-modifying therapies closes.
The TMMT Role: Optimizing Cognitive Care in the Community
The introduction of these drugs creates a massive logistical challenge for Canadian primary care. These aren’t “prescribe and forget” medications; they require a high level of clinical governance.
How TMMT Supports the Transition:
- Medication Reconciliation: Patients in the early stages of Alzheimer’s are often on multiple medications for other conditions (hypertension, diabetes). Our remote clinical pharmacists ensure that there are no contraindications, especially with blood thinners, which can increase the risk of ARIA.
- Monitoring Protocols: We help practices implement the rigorous MRI and infusion schedules required for Leqembi and Kisunla.
- Patient Education: Our teams provide the clear, grounded communication that families need to understand that while these drugs are a historic breakthrough, they are not a cure. They are a way to buy more “meaningful time.”
Conclusion: A New Horizon for Canadian Seniors
The approval of Lecanemab and Donanemab marks the end of the “era of helplessness” in Alzheimer’s care. We have moved from a time when we could only watch the disease progress to a time when we can actively intervene in its machinery.
However, “authorized” does not yet mean “accessible.” The next two years will be a period of intense advocacy to ensure these treatments are covered by provincial health plans and that the infrastructure for early diagnosis is strengthened.
Timing is everything. These drugs only work when the brain’s “architecture” is still largely intact. If you or a loved one are noticing the early signs of memory loss, a timely diagnosis is no longer just about planning for the future, it’s about qualifying for the present.
FAQ: Frequently Asked Questions
No. They are disease-modifying therapies that slow down the progression of the disease by removing amyloid plaques. They cannot reverse damage that has already occurred or restore lost memories.
Currently, they are only approved for people with Mild Cognitive Impairment (MCI) or early-stage Alzheimer’s disease. They are not intended for people with moderate or severe dementia, or for other types of dementia like Frontotemporal or Vascular dementia.
Lecanemab is usually given every two weeks and targets the “building blocks” of plaques. Donanemab is given once a month and targets the “mature” plaques. Donanemab also allows for treatment to stop once the plaques are gone, whereas Lecanemab is often ongoing.
People with two copies of the APOE4 gene are at a higher risk of developing ARIA (brain swelling or bleeding) while on these medications. Knowing your genetic status helps your doctor determine if the benefits of the drug outweigh the risks.
While Health Canada has approved them, public funding (e.g., OHIP, Pharmacare) usually takes 1-2 years to finalize after a review by bodies like CADTH. Private insurance may cover them sooner.
No. The ASC stresses that a thorough clinical assessment is required. These drugs are only for those with confirmed amyloid plaques in the brain and who are in the very early stages of cognitive decline.
The ASC encourages Canadians to contact their provincial representatives to advocate for the inclusion of disease-modifying therapies in public drug formularies and to support investments in diagnostic infrastructure.
